The Utility of Peptide Ligand-Functionalized Liposomes for Subcutaneous Drug Delivery for Arthritis Therapy
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24086883 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Hemalatha Nanjaiah und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD 21201, USA. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Arthritis, Experimental. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Silo Pharma, sponsored research agreement, Silo Pharma, Inc..
Abstract (Originalsprache)
Liposomes and other types of nanoparticles are increasingly being explored for drug delivery in a variety of diseases. There is an impetus in the field to exploit different types of ligands to functionalize nanoparticles to guide them to the diseased site. Most of this work has been conducted in the cancer field, with relatively much less information from autoimmune diseases, such as rheumatoid arthritis (RA). Furthermore, in RA, many drugs are self-administered by patients subcutaneously (SC). In this context, we have examined the attributes of liposomes functionalized with a novel joint-homing peptide (denoted ART-1) for arthritis therapy using the SC route. This peptide was previously identified following phage peptide library screening in the rat adjuvant arthritis (AA) model. Our results show a distinct effect of this peptide ligand on increasing the zeta potential of liposomes. Furthermore, liposomes injected SC into arthritic rats showed preferential homing to arthritic joints, following a migration profile in vivo similar to that of intravenously injected liposomes, except for a less steep decline after the peak. Finally, liposomal dexamethasone administered SC was more effective than the unpackaged (free) drug in suppressing arthritis progression in rats. We suggest that with suitable modifications, this SC liposomal treatment modality can be adapted for human RA therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
- Division of Rheumatology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Förderung
- Silo Pharma
- sponsored research agreement
- Silo Pharma, Inc.
Zitieren
APA
Nanjaiah, H., & Moudgil, K. D. (2023). The Utility of Peptide Ligand-Functionalized Liposomes for Subcutaneous Drug Delivery for Arthritis Therapy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24086883
Vancouver
Nanjaiah H, Moudgil KD. The Utility of Peptide Ligand-Functionalized Liposomes for Subcutaneous Drug Delivery for Arthritis Therapy. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24086883
BibTeX
@article{Nanjaiah2023,
author = {Nanjaiah, Hemalatha and Moudgil, Kamal D},
title = {The Utility of Peptide Ligand-Functionalized Liposomes for Subcutaneous Drug Delivery for Arthritis Therapy},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24086883}
}
EUVIMED